Last $6.72 USD
Change Today +0.32 / 5.00%
Volume 464.8K
XNPT On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

xenoport inc (XNPT) Snapshot

Open
$6.42
Previous Close
$6.40
Day High
$6.75
Day Low
$6.31
52 Week High
01/13/14 - $7.20
52 Week Low
05/9/14 - $3.15
Market Cap
418.1M
Average Volume 10 Days
588.0K
EPS TTM
$-1.46
Shares Outstanding
62.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for XENOPORT INC (XNPT)

xenoport inc (XNPT) Related Businessweek News

No Related Businessweek News Found

xenoport inc (XNPT) Details

XenoPort, Inc., a biopharmaceutical company, focuses on developing and commercializing a portfolio of internally discovered product candidates for the treatment of neurological and other disorders. It markets HORIZANT (gabapentin enacarbil) extended-release tablets for the treatment of moderate-to-severe primary restless legs syndrome, as well as for the management of postherpetic neuralgia in adults in the United States. The company is also developing XP23829, a fumaric acid ester compound and a patented prodrug of monomethyl fumarate, which is being studied in a Phase I clinical trial for the treatment of psoriasis and/or relapsing forms of multiple sclerosis. In addition, it is developing product candidates that have completed Phase II clinical trial, including arbaclofen placarbil, a potential treatment for spasticity in patients with spinal cord injury; and XP21279, a potential treatment for patients with advanced idiopathic Parkinson’s disease. The company has strategic alliance with Astellas Pharma Inc. to develop and commercialize Gabapentin Enacarbil under the Regnite name in Japan. XenoPort, Inc. was founded in 1999 and is based in Santa Clara, California.

92 Employees
Last Reported Date: 02/28/14
Founded in 1999

xenoport inc (XNPT) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: $500.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $369.2K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $426.4K
Chief Legal Officer, Senior Vice President an...
Total Annual Compensation: $353.9K
Senior Vice President of Regulatory Affairs &...
Total Annual Compensation: $336.0K
Compensation as of Fiscal Year 2013.

xenoport inc (XNPT) Key Developments

XenoPort, Inc. and the National Institute on Alcohol Abuse & Alcoholism Announce Clinical Trial Agreement to Study Horizant as Potential Treatment for Alcohol Use Disorder

XenoPort, Inc. and the National Institute on Alcohol Abuse and Alcoholism announced that they have entered into an agreement to conduct a clinical trial of HORIZANT(R) (gabapentin enacarbil) Extended-Release Tablets as a potential treatment for alcohol use disorder (AUD). Under the terms of the agreement, XenoPort will supply clinical trial material and the NIAAA will conduct and pay all other expenses associated with the proposed clinical trial of HORIZANT. XenoPort will have access to study results generated under the proposed clinical trial to support potential regulatory filings for HORIZANT. The study is planned to be a randomized, double-blind, placebo-controlled clinical trial of the safety and efficacy of HORIZANT in patients who have AUD but are abstinent at treatment initiation. The study is expected to have a treatment period of six months and to enroll approximately 350 patients beginning in the first half of 2015. XenoPort and the NIAAA are planning to meet with the U.S. Food and Drug Administration (FDA) Division of Anesthesia, Analgesia and Addiction Products in the fourth quarter of 2014 to discuss the trial design and the possibility of utilizing the results of this trial as the basis for a potential supplemental new drug application (sNDA) submission for HORIZANT for the maintenance of abstinence from heavy drinking of alcohol in patients with AUD.

XenoPort, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 04:40 PM

XenoPort, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 04:40 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Ronald W. Barrett, Co-Founder, Chief Executive Officer and Director.

Xenoport, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Xenoport, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company's total revenues were $5,334,000 compared to $2,086,000 a year ago. Loss from operations was $19,333,000 compared to $24,187,000 a year ago. Net loss was $19,387,000 compared to $24,381,000 a year ago. Basic and diluted net loss per share was $0.31 compared to $0.51 a year ago. For the six months, the company's total revenues were $8,709,000 compared to $2,545,000 a year ago. Loss from operations was $39,816,000 compared to $47,816,000 a year ago. Net loss was $39,935,000 compared to $47,929,000 a year ago. Basic and diluted net loss per share was $0.67 compared to $1.01 a year ago. The increase in revenues in both the second quarter and six months ended June 30, 2014 was principally due to HORIZANT net product sales, which totaled $4.9 million and $7.9 million for the second quarter and six months ended June 30, 2014, respectively.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XNPT:US $6.72 USD +0.32

XNPT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioDelivery Sciences International Inc $16.62 USD +0.24
Depomed Inc $15.10 USD -0.12
Flamel Technologies SA $12.77 USD -0.20
Merrion Pharmaceuticals Plc €0.38 EUR 0.00
PlasmaTech Biopharmaceuticals Inc $10.00 USD -1.00
View Industry Companies
 

Industry Analysis

XNPT

Industry Average

Valuation XNPT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 29.5x
Price/Book 4.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 20.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact XENOPORT INC, please visit www.xenoport.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.